Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Clinical Chemistry|September 7, 2021
CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid MalignanciesEitan Halper-Stromberg, Chad M McCall, Lisa M Haley, et al.
NMR in Biomedicine|April 19, 2026
Unique Peritumoral Patterns Unveiled by Quantitative Multiparametric MRI and Their Diagnostic and Prognostic Value in Treated Malignant GliomasKeyi Chai, Puyang Wang, Austin Carmichael, et al.
Neuro-Oncology Advances|August 9, 2023
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomasMatthias Holdhoff, M Kelly Nicholas, Richard A Peterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in patients with lower-grade glioma: an in vivo MR Spectroscopy studyDunja Simicic, Seyma Alcicek, Lindsay Blair, et al.
British Journal of Cancer|December 5, 2022
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignanciesOana C Danciu, Matthias Holdhoff, Richard A Peterson, et al.
Cell Reports. Medicine|July 2, 2024
A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)Manmeet S Ahluwalia, Ahmad Ozair, Michelle Rudek, et al.
Frontiers in Immunology|September 19, 2024
The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatmentEdina Komlodi-Pasztor, Marta Escarra-Senmarti, Danielle A Bazer, et al.
Acta Neuropathologica Communications|October 30, 2024
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomesMichael Chang, Mohamed Sherief, Maria Ioannou, et al.
Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology Advances|January 28, 2021
Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trialGary L Gallia, Matthias Holdhoff, Henry Brem, et al.
Pageof 12